Contact Us
Technology
Therapeutic Focus
News and Events
The truth about why we need this COVID-19 treatment right now!
By Grant Ellis, Director NovaBiotics Ltd On Monday we learnt from Sir Patrick Vallance, the government’s Chief Scientific Adviser that Coronavirus will probably never disappear and a vaccine won't stop it completely. He also said that ministers and experts should...
NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.
We are in the midst of a worsening global antimicrobials resistance (AMR) crisis. There is an urgent need for new classes of antibacterial, antifungal and other antimicrobial treatments to address range of challenging infectious diseases that can no longer be resolved with existing drugs. NovaBiotics is a leading innovator in the anti-infectives space and we are designing and developing new medicines that are potential solutions not only to the AMR crisis, but also for complex diseases with an infectious component such as the respiratory infections associated with cystic fibrosis (CF).
NovaBiotics was founded by our CEO, Dr. Deborah O’Neil in 2004 and operates from sites in Aberdeen, UK (R&D headquarters), Dublin, Ireland and Boston (MA), U.S. The Company has a successful track record of invention to clinic of its portfolio of therapeutic candidates. These first in class antimicrobials have been developed from our two proprietary Technology platforms which are underpinned by an extensive, wholly owned intellectual property estate.
The Company’s advanced portfolio of antimicrobial therapeutic candidates targets large and important markets with significant unmet clinical needs, including NM002 (Nylexa®), an antibiotic potentiator for drug resistant bacterial infections including the secondary bacterial infections associated with COVID-19, NM001 (Lynovex®), an orphan drug candidate for cystic fibrosis (CF) and NP339, a novel antifungal peptide in development primarily for the treatment of invasive fungal diseases caused by mould & emerging, drug resistant yeasts. NP423 (Novarifyn®) is a bactericidal peptide for difficult to treat Gram negative and Gram positive bacteria and NP213 (Novexatin®), a potential step change therapy for onychomycosis.